Hikal develops generic API of Avigan

Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation

Published On 2020-05-17 06:30 GMT   |   Update On 2020-05-17 06:30 GMT
Advertisement

Mumbai: Drugmaker Hikal Limited has recently announced the successful development of Favipiravir Active Pharmaceutical ingredient (API) and its intermediates.

Favipiravir is a generic version of Avigan of Fujifilm Toyama Chemical Co. Ltd., Japan, a subsidiary of Fujifilm Corporation. Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections. It is in various stages of clinical trials in many countries as an experimental treatment of COVID-19.

"The company is in discussion with potential partners to supply the API and its intermediates," Hikal said in its recent release

Hikal Ltd is a global manufacturer and supplier of API's and intermediates, headquartered in India.

Hikal provides world-class active ingredients, intermediates and R&D services to global pharmaceuticals, animal health, biotech, crop protection and speciality chemicals companies.

The Company has five manufacturing facilities in India at Maharashtra (Taloja and Mahad), Gujarat (Panoli) and Karnataka (Jigani) and a Research & Technology centre at Maharashtra (Pune).

Read also: Glenmark begins Phase 3 Clinical Trials on Antiviral Favipiravir for coronavirus in India


Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News